Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms
暂无分享,去创建一个
J. Krystal | J. Seibyl | D. Charney | A. Abi-Dargham | G. Heninger | L. Karper | C. D’Souza | J. Erdos | W. Abi-Saab | M. Wong | Ralitza Gueorgueva | Sachin Rajhans
[1] G. Gessa,et al. The 5-HT2 antagonist ritanserin blocks dopamine re-uptake in the rat frontal cortex , 2000, Molecular Psychiatry.
[2] M. Teitler,et al. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[3] J. Leander,et al. A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon , 2000, Behavioural pharmacology.
[4] Leander Jd,et al. A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon. , 2000 .
[5] J. Neumaier,et al. Clozapine downregulates 5-hydroxytryptamine6 (5-HT6) and upregulates 5-HT7 receptors in HeLa cells , 2000, Neuroscience Letters.
[6] M. Wood,et al. Antagonist activity of meta-chlorophenylpiperazine and partial agonist activity of 8-OH-DPAT at the 5-HT(7) receptor. , 2000, European journal of pharmacology.
[7] G. Aghajanian,et al. Serotonin model of schizophrenia: emerging role of glutamate mechanisms , 2000, Brain Research Reviews.
[8] M. Heo,et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.
[9] J. Krystal,et al. Symptom provocation studies in psychiatric disorders: scientific value, risks, and future , 1999, Biological Psychiatry.
[10] W. Carpenter. The schizophrenia ketamine challenge study debate , 1999, Biological Psychiatry.
[11] R. Porter,et al. Functional characterization of agonists at recombinant human 5‐HT2A, 5‐HT2B and 5‐HT2C receptors in CHO‐K1 cells , 1999, British journal of pharmacology.
[12] J. Frederick,et al. Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain , 1999, Schizophrenia Research.
[13] D. Greenblatt,et al. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions , 1999, Psychopharmacology.
[14] B. Roth,et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo , 1999, Neuroscience.
[15] S. Potkin,et al. Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial , 1999, Neuropsychopharmacology.
[16] S. Tsai,et al. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. , 1999, Neuroreport.
[17] M. Millan,et al. Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO60-0175: a pharmacological analysis , 1999, Neuropharmacology.
[18] E. Eriksson,et al. Effects of mCPP on the Extracellular Concentrations of Serotonin and Dopamine in Rat Brain , 1999, Neuropsychopharmacology.
[19] S. Kapur,et al. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. , 1999, The American journal of psychiatry.
[20] G. Tollefson,et al. Review of recent clinical studies with olanzapine , 1999, British Journal of Psychiatry.
[21] M. Göthert,et al. Genetic Variation in Human 5‐HT Receptors: Potential Pathogenetic and Pharmacological Role a , 1998, Annals of the New York Academy of Sciences.
[22] M. Teitler,et al. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.
[23] R. Schreiber,et al. Role of 5-HT1B, 5-HT2A and 5-HT2C receptors in the generalization of 5-HT receptor agonists to the ethanol cue in the rat. , 1998, Behavioural pharmacology.
[24] T. Hijzen,et al. Discriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action , 1998, Psychopharmacology.
[25] H. Grill,et al. Serotonin receptors in the caudal brainstem are necessary and sufficient for the anorectic effect of peripherally administered mCPP , 1998, Psychopharmacology.
[26] J. Terrón,et al. Effects of the 5-HT receptor antagonists GR127935 (5-HT1B/1D) and MDL100907 (5-HT2A) in the consolidation of learning , 1997, Behavioural Brain Research.
[27] R. Rosenheck,et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.
[28] L. Arvanitis,et al. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.
[29] P. Cowen,et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects , 1997, Psychopharmacology.
[30] H. Meltzer,et al. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers , 1996, Psychiatry Research.
[31] R. Littell. SAS System for Mixed Models , 1996 .
[32] A. Brown,et al. m-Chlorophenylpiperazine (mCPP) is an antagonist at the cloned human 5-HT2B receptor. , 1996, Neuroreport.
[33] A. Sleight,et al. Pharmacologic evaluation of the discriminative stimulus of metachlorophenylpiperazine , 1996, Pharmacology Biochemistry and Behavior.
[34] D. Mash,et al. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. , 1995, Neuroreport.
[35] H. Meltzer,et al. Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men , 1995, Psychiatry Research.
[36] B. Bunney,et al. Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. , 1995, The Journal of pharmacology and experimental therapeutics.
[37] D. Sibley,et al. Clozapine: Selective Labeling of Sites Resembling 5HT6 Serotonin Receptors May Reflect Psychoactive Profile , 1995, Molecular medicine.
[38] J. Lieberman,et al. The Behavioral Effect of m-Chlorophenylpiperazine (mCPP) and Methylphenidate in First-Episode Schizophrenia and Normal Controls , 1995, Neuropsychopharmacology.
[39] M. Grotewiel,et al. m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. , 1994, The Journal of pharmacology and experimental therapeutics.
[40] P. Cowen,et al. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers , 1994, Biological Psychiatry.
[41] L. Siever,et al. Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine , 1994, Biological Psychiatry.
[42] K. Cunningham,et al. Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). , 1994, European journal of pharmacology.
[43] R. Buchanan,et al. Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia , 1993, Biological Psychiatry.
[44] K. Davis,et al. Serotonin function and treatment response to clozapine in schizophrenic patients. , 1993, The American journal of psychiatry.
[45] S. Woods,et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. , 1993, Archives of general psychiatry.
[46] J. Hsiao,et al. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. , 1993, Archives of general psychiatry.
[47] L. Siever,et al. Serotonin function in schizophrenia: Effects of meta- chlorophenylpiperazine in schizophrenia patients and healthy subjects , 1992, Psychiatry Research.
[48] G. Aghajanian,et al. Excitatory responses to serotonin (5‐HT) in neurons of the rat piriform cortex: Evidence for mediation by 5‐HT1C receptors in pyramidal cells and 5‐HT2 receptors in interneurons , 1991, Synapse.
[49] R. Kahn,et al. The MCPP challenge test in schizophrenia: Hormonal and behavioral responses , 1991, Biological Psychiatry.
[50] S. Woods,et al. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects , 1991, Psychiatry Research.
[51] H. Meltzer. Role of serotonin in the action of atypical antipsychotic drugs. , 1990, Clinical neuroscience.
[52] W. Cahn,et al. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects , 1990, Psychiatry Research.
[53] H. Meltzer,et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.
[54] R. Glennon,et al. Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. , 1989, European journal of pharmacology.
[55] D. Hoyer,et al. Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? , 1989, Naunyn-Schmiedeberg's Archives of Pharmacology.
[56] G. Kennett,et al. Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. , 1989, European journal of pharmacology.
[57] S. Peroutka,et al. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain , 1989, Biological Psychiatry.
[58] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[59] P. Conn,et al. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. , 1987, The Journal of pharmacology and experimental therapeutics.
[60] J. Csernansky,et al. Rating scales in research: The case of negative symptoms , 1987, Psychiatry Research.
[61] J. Leysen,et al. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. , 1985, Molecular pharmacology.
[62] J. Gerlach,et al. CLOZAPINE AND HALOPERIDOL IN A SINGLE‐BLIND CROSS‐OVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA , 1974, Acta psychiatrica Scandinavica.
[63] H. Meltzer,et al. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs , 1999, European Archives of Psychiatry and Clinical Neuroscience.
[64] C. Nemeroff,et al. New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine , 1998, Depression and anxiety.
[65] D. Collier,et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine , 1998, Molecular Psychiatry.
[66] G. Aghajanian,et al. The role of serotonin in the pathophysiology and treatment of schizophrenia. , 1997, The Journal of neuropsychiatry and clinical neurosciences.
[67] Nancy H. Covell,et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. , 1996, Psychopharmacology bulletin.
[68] R. Buchanan,et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. , 1994, The American journal of psychiatry.
[69] D. Wong,et al. mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors. , 1992, Life sciences.
[70] A. Björk,et al. Amperozide: a new pharmacological approach in the treatment of schizophrenia. , 1990, Pharmacology & toxicology.
[71] M. Woerner,et al. Anchoring the BPRS: an aid to improved reliability. , 1988, Psychopharmacology bulletin.